MXPA03004029A - Metodos para tratamiento de trastornos proliferativos celulares. - Google Patents

Metodos para tratamiento de trastornos proliferativos celulares.

Info

Publication number
MXPA03004029A
MXPA03004029A MXPA03004029A MXPA03004029A MXPA03004029A MX PA03004029 A MXPA03004029 A MX PA03004029A MX PA03004029 A MXPA03004029 A MX PA03004029A MX PA03004029 A MXPA03004029 A MX PA03004029A MX PA03004029 A MXPA03004029 A MX PA03004029A
Authority
MX
Mexico
Prior art keywords
proliferative disorders
methods
treatment
cellular proliferative
reovirus
Prior art date
Application number
MXPA03004029A
Other languages
English (en)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of MXPA03004029A publication Critical patent/MXPA03004029A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/115Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135Respiratory syncytial virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/14Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
MXPA03004029A 2000-11-09 2001-10-26 Metodos para tratamiento de trastornos proliferativos celulares. MXPA03004029A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24672800P 2000-11-09 2000-11-09
PCT/CA2001/001512 WO2002039117A1 (en) 2000-11-09 2001-10-26 Methods for the treatment of cellular proliferative disorders

Publications (1)

Publication Number Publication Date
MXPA03004029A true MXPA03004029A (es) 2004-02-12

Family

ID=22931950

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004029A MXPA03004029A (es) 2000-11-09 2001-10-26 Metodos para tratamiento de trastornos proliferativos celulares.

Country Status (17)

Country Link
US (3) US7052832B2 (es)
EP (2) EP2189162B1 (es)
JP (2) JP4146725B2 (es)
AR (1) AR031281A1 (es)
AT (1) ATE472733T1 (es)
AU (2) AU1202202A (es)
BR (1) BR0115235A (es)
CA (1) CA2428206C (es)
DE (1) DE60142485D1 (es)
DK (2) DK1332366T3 (es)
ES (2) ES2347523T3 (es)
HK (1) HK1142833A1 (es)
IL (1) IL154881A0 (es)
MX (1) MXPA03004029A (es)
NZ (1) NZ524937A (es)
WO (1) WO2002039117A1 (es)
ZA (1) ZA200302086B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
ES2551306T3 (es) * 2006-02-13 2015-11-17 Oncolytics Biotech Inc. Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica
WO2008031230A1 (en) * 2006-09-15 2008-03-20 Dalhousie University Methods of determining susceptibility of cells to reovirus infection and methods for treating cellular proliferative disorders with reovirus
KR101647843B1 (ko) 2007-03-12 2016-08-11 온콜리틱스 바이오테크 인코포레이티드 변형된 서열을 갖는 레오바이러스
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW200909581A (en) * 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
WO2009052617A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
TWI399369B (zh) 2008-04-02 2013-06-21 Nat Defense Medical Ct 咪唑蒽醌衍生物及其合成方法
MX2010012857A (es) * 2008-05-27 2010-12-20 Oncolytics Biotech Inc Supresion de produccion de citoquina proinflamatoria durante la terapia de reovirus oncolitico.
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US20180305345A1 (en) 2015-01-26 2018-10-25 Ottawa Hospital Research Institute Compositions and methods for enhancing oncolytic virus efficacy
PT3518948T (pt) 2016-10-03 2023-07-17 Ottawa Hospital Res Inst Composições e métodos para melhorar o crescimento, a propagração e a eficácia imunoterapêutica de oncolítica de vírus de rna oncolíticos
CA2971832A1 (en) * 2017-06-23 2018-12-23 Roy Duncan Recombinant oncolytic viruses for treatment of metastatic cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia

Also Published As

Publication number Publication date
CA2428206A1 (en) 2002-05-16
AR031281A1 (es) 2003-09-17
IL154881A0 (en) 2003-10-31
EP2189162B1 (en) 2013-11-27
JP4146725B2 (ja) 2008-09-10
AU1202202A (en) 2002-05-21
ES2445704T3 (es) 2014-03-04
NZ524937A (en) 2004-10-29
WO2002039117A1 (en) 2002-05-16
ES2347523T3 (es) 2010-11-02
EP1332366B1 (en) 2010-06-30
ZA200302086B (en) 2004-03-15
US7815914B2 (en) 2010-10-19
JP2008268200A (ja) 2008-11-06
DE60142485D1 (de) 2010-08-12
DK1332366T3 (da) 2010-08-02
US20060172288A1 (en) 2006-08-03
ATE472733T1 (de) 2010-07-15
CA2428206C (en) 2005-09-27
EP1332366A1 (en) 2003-08-06
EP2189162A1 (en) 2010-05-26
US7052832B2 (en) 2006-05-30
JP2004512385A (ja) 2004-04-22
US7763252B2 (en) 2010-07-27
HK1142833A1 (en) 2010-12-17
BR0115235A (pt) 2003-10-14
AU2002212022B2 (en) 2006-03-30
DK2189162T3 (da) 2014-02-03
US20020086284A1 (en) 2002-07-04
US20080057073A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
MXPA03004029A (es) Metodos para tratamiento de trastornos proliferativos celulares.
DE60027768D1 (de) Behandlung von metastatischer krankheit
NZ514628A (en) Use of inhibitors for inducing cancer cell death and tumor regression
Abbasnia et al. The effects of repetitive transcranial magnetic stimulation on proliferation and differentiation of neural stem cells
YU65502A (sh) Supstituisani beta-karbolini sa ikb-kinaza inhibirajućim dejstvom
Bai et al. Melatonin improves reprogramming efficiency and proliferation of bovine‐induced pluripotent stem cells
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
Cunningham et al. Protease nexin-1 and thrombin: injury-related processes in the brain
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
TW200634010A (en) Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
MX2022016355A (es) Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
NO20031531L (no) Fremgangsmater for induksjon av kreftcelledod og tumorregresjon
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
Moradi et al. Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells
WO2005089518A3 (en) Uch-l1 expression and cancer therapy
Kuo et al. Reversion of the transformed phenotypes of vH-ras NIH3T3 cells by flavonoids through attenuating the content of phosphotyrosine
ATE346147T1 (de) Zusammensetzungen und methoden zur wundheilung

Legal Events

Date Code Title Description
FG Grant or registration